Search Result

Results for "

hydroxy bile acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Antibiotic (1) Biochemical Assay Reagents (1) Drug Isomer (1) Endogenous Metabolite (12) Ephrin Receptor (1) FXR (2) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (1) PDGFR (1) Reference Standards (6) VEGFR (1)
By Research Areas:	Cancer (2) Infection (1) Metabolic Disease (15) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113315

3b-Hydroxy-5-cholenoic acid	Endogenous Metabolite	Metabolic Disease
3β-Hydroxy-5-cholenoic acid is a steroidal monohydroxy bile acid and serves as a substrate for sulfation reactions. It is applicable to the research of extrahepatic biliary atresia and recurrent intrahepatic cholestasis of pregnancy .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-W018512

7-Ketolithocholic acid 4 Publications Verification 3α-hydroxy-7-oxo-5β-cholanic acid	Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7	Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-W018512R

7-Ketolithocholic acid (Standard) 3α-hydroxy-7-oxo-5β-cholanic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-106380

Glenvastatin HR 780	HMG-CoA Reductase (HMGCR)	Metabolic Disease
Glenvastatin (HR 780) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Glenvastatin can reduces plasma total cholesterol and phospholipid levels and liver cholesterol contents. Glenvastatin does not increase the contents of cholesterol and total bile acid in the gallbladder bile. Glenvastatin can be used for the research of hyperlipemia

HY-164293

Methyl (5α,7α)-7-hydroxy-3-oxocholan-24-oate	Endogenous Metabolite	Metabolic Disease
Methyl (5α,7α)-7-hydroxy-3-oxocholan-24-oate (compound 7a) is a bile acid metabolite .

HY-42225

Methyl 7α-hydroxy-3-ketocholanoate	Biochemical Assay Reagents	Others Neurological Disease
Methyl 7α-hydroxy-3-ketocholanoate is a bile acid compound that can be used in neurological disease research .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-124265R

4β-Hydroxycholesterol (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
4β-hydroxy Cholesterol (Standard) is the analytical reference standard of 4β-hydroxy Cholesterol (HY-124265). This product is used for research and analytical applications. 4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation .

HY-201296A

Tauroursocholic acid sodium TUCA sodium	Drug Isomer	Cancer
Tauroursocholic acid (TUCA) sodium is a taurine-conjugated form of the bile acid ursocholic acid and the 7β-hydroxy epimer of Taurocholic acid (HY-B1788). Tauroursocholic acid sodium exists in abundance during the biliary tract cancer, disrupting the balance and cellular toxicity of bile acids and inducing carcinogenesis through oxidative DNA damage and DNA mutation. Tauroursocholic acid (TUCA) sodium can be used for biliary tract cancer research .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-138026

(3β)-3-Hydroxy-7-oxochol-5-en-24-oic acid	Endogenous Metabolite	Metabolic Disease
(3β)-3-Hydroxy-7-oxochol-5-en-24-oic acid is a bile acid, and is a metabolite of 7β-hydroxy cholesterol (HY-113341) .

HY-113315S

3b-Hydroxy-5-cholenoic acid-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
3b-Hydroxy-5-cholenoic acid-d4 is deuterium labeled 3b-Hydroxy-5-cholenoic acid (HY-113315). 3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin .

HY-113315R

3b-Hydroxy-5-cholenoic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
3b-Hydroxy-5-cholenoic acid (Standard) is an analytical standard for 3b-Hydroxy-5-cholenoic acid. This product is intended for research and analytical applications. 3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin. 3b-Hydroxy-5-cholenoic acid can be used in the study of hepatic ductular hypoplasia syndrome .

HY-129123R

ML318 (Standard)	Reference Standards Antibiotic	Infection
7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-E70408

12α-Hydroxysteroid dehydrogenase, bacillus sphaericus	Endogenous Metabolite	Metabolic Disease
12α-Hydroxysteroid dehydrogenase, bacillus sphaericus is a dehydrogenase expressed in Bacillus sphaericus. 12α-Hydroxysteroid dehydrogenase, bacillus sphaericus is NAD-dependent and is active on both bound and unbound bile salts. This enzyme can be used to measure the concentration of 12α-hydroxy bile acids in serum .

HY-16265A

JI-101 hydrochloride	Ephrin Receptor PDGFR VEGFR	Cancer
JI-101 hydrochloride is an orally active angiogenesis inhibitor and anticancer agent with 55% oral bioavailability in Sprague Dawley rats, high permeability, and no P-gp substrate activity .JI-101 hydrochloride modulates angiogenesis signaling pathways in tumor vessel beds, downregulates EphB4, targets EphB4, VEGFR-2, and PDGFR-β, and inhibits multiple stages of tumor angiogenesis .JI-101 hydrochloride exerts activity against cancer cells and xenografts, exhibits mild to moderate inhibition of CYP3A4, and shows stability in pre-clinical and human liver microsomes .JI-101 hydrochloride undergoes rapid oral absorption in Sprague Dawley rats, has extensive tissue distribution with preferred lung uptake, and is excreted via bile with mono- and di-hydroxy metabolites, with feces as the primary elimination route .JI-101 hydrochloride can be used for the research of ovarian cancer and solid tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113315

3b-Hydroxy-5-cholenoic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
3β-Hydroxy-5-cholenoic acid is a steroidal monohydroxy bile acid and serves as a substrate for sulfation reactions. It is applicable to the research of extrahepatic biliary atresia and recurrent intrahepatic cholestasis of pregnancy .

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-W018512

7-Ketolithocholic acid 4 Publications Verification 3α-hydroxy-7-oxo-5β-cholanic acid	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-W018512R

7-Ketolithocholic acid (Standard) 3α-hydroxy-7-oxo-5β-cholanic acid (Standard)	Structural Classification Microorganisms Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Reference Standards Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-124265R

4β-Hydroxycholesterol (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
4β-hydroxy Cholesterol (Standard) is the analytical reference standard of 4β-hydroxy Cholesterol (HY-124265). This product is used for research and analytical applications. 4β-Hydroxycholesterol is a major Cholesterol (HY-N0322) metabolite and a precursor in the synthesis of bile acids that is found in human circulation .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-113315R

3b-Hydroxy-5-cholenoic acid (Standard)	Structural Classification Microorganisms Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
3b-Hydroxy-5-cholenoic acid (Standard) is an analytical standard for 3b-Hydroxy-5-cholenoic acid. This product is intended for research and analytical applications. 3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin. 3b-Hydroxy-5-cholenoic acid can be used in the study of hepatic ductular hypoplasia syndrome .

Cat. No.	Product Name	Chemical Structure

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7
7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

7α-Hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-113315S

3b-Hydroxy-5-cholenoic acid-d4
3b-Hydroxy-5-cholenoic acid-d4 is deuterium labeled 3b-Hydroxy-5-cholenoic acid (HY-113315). 3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

hydroxy bile acid

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products